M3 and the associated logos are trademarks of M3 USA Corporation and M3 Inc.

M3 USA is a leading healthcare technology and services company that connects life sciences organizations with physicians, patients, and healthcare systems to accelerate clinical research, improve communication, and optimize outcomes. As a subsidiary of M3, Inc.—a global leader in digital health—M3 USA plays a critical role in supporting education, recruitment, and data-driven insights across a broad spectrum of therapeutic areas, including metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).

Through its network of subsidiaries—including MDLinx, M3 Global Research, and Wake Research—M3 USA empowers biopharmaceutical companies developing novel therapies for MASH with end-to-end clinical trial support, including physician engagement, protocol optimization, patient recruitment, and real-world evidence generation. These services are essential for accelerating timelines and ensuring trials reflect the diverse populations most impacted by MASLD-related liver complications.

M3 USA also provides medical education and digital outreach solutions, helping healthcare providers stay current on emerging trends in MASH diagnostics, non-invasive assessment tools, and evolving treatment paradigms. By leveraging a vast network of verified HCPs and advanced targeting technologies, M3 USA ensures the right messages reach the right audiences at the right time—amplifying the impact of innovation in liver disease care.

With a strong commitment to advancing precision medicine and reducing healthcare disparities, M3 USA is uniquely positioned to support the next generation of therapeutic breakthroughs in MASLD/MASH by bridging science, practice, and patient care at scale.